Evidence map›Paper›PMID 41588216›Full record

ArticleOphthalmology and therapy2026

Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Undergoing Cataract Surgery: A Prospective Multicenter Study.

John A Hovanesian, Eva Liang, Neel R Desai, Gregg J Berdy, Kayla Karpuk, Justin Schweitzer, Adam Alexander, Jason L Vittitow, John Berdahl, Jason Bacharach

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06346340 (A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06346340 phase4completednot on this map

A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy

TypeinterventionalSponsorBausch & Lomb IncorporatedRan2024 to 2025Enrolled97ConditionsDry EyeArmsMiebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

John A HovanesianHarvard Eye Associates, Laguna Hills, CA, USA.
Eva LiangCenter for Sight, Las Vegas, NV, USA.
Neel R DesaiThe Eye Institute of West Florida, Largo, FL, USA.
Gregg J BerdyOphthalmology Associates, St Louis, MO, USA.
Kayla KarpukVance Thompson Vision, Sioux Falls, SD, USA.
Justin SchweitzerVance Thompson Vision, Sioux Falls, SD, USA.
Adam AlexanderBausch + Lomb, Bridgewater, NJ, USA.
Jason L VittitowBausch + Lomb, Bridgewater, NJ, USA.
John BerdahlVance Thompson Vision, Sioux Falls, SD, USA.
Jason BacharachNorth Bay Eye Associates, Inc., 104 Lynch Creek Way, Suite 15, Petaluma, CA, 94954, USA. jbacharach@northbayeye.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDry eye disease (DED) is a common comorbidity in patients undergoing cataract surgery. Perfluorohexyloctane ophthalmic solution (PFHO) forms a protective layer on the tear film surface to reduce evaporation and is approved for treatment of signs and symptoms of DED. Because PFHO has a long ocular surface residence time, it was of interest to assess whether PFHO interfered with preoperative biometry and keratometry measurements to affect postoperative refractive accuracy in patients undergoing cataract surgery. This study evaluated the perioperative use of PFHO in patients undergoing cataract surgery.

methodsThis phase 4, multicenter, open-label, single-arm study enrolled patients with DED who were candidates for phacoemulsification with posterior chamber intraocular lens (IOL) implantation. Patients instilled PFHO bilaterally four times daily for 30 days preoperatively and received a second 30-day PFHO treatment approximately 1 month after surgery. The primary endpoint was the mean difference in absolute deviations between the manifest refraction spherical equivalent and predicted refractive error.

resultsNinety-seven patients were enrolled (mean age: 68.6 years; female: 75.3%). The mean difference in absolute deviations between manifest refraction and predicted refractive error was -0.027 ± 0.167 D (p = 0.1385). The difference in predicted refractive error at baseline versus post-PFHO treatment was within ± 0.3 D for 94.2% of study eyes. More patients had a calculated IOL power within ± 0.50 D of the correct IOL power post-PFHO treatment than pre-PFHO (83.7% vs. 72.1%). Treatment with PFHO significantly improved DED signs and symptoms, including total and central corneal fluorescein staining, eye dryness, and Ocular Surface Disease Index scores, before and after cataract surgery (p < 0.0001 for all). The percentage of patients with best-corrected visual acuity of 20/20 or better was 86.0% at first postsurgical assessment and 91.8% after 30 days of subsequent PFHO treatment. Two adverse events were considered related to treatment (mild eye pruritus and mild noninfectious conjunctivitis).

conclusionsIn patients with DED undergoing cataract surgery, PFHO did not affect the accuracy of preoperative biometry and keratometry measurements or the predicted refractive error. Patients experienced significant reductions in signs and symptoms of DED.

trial registrationClinicalTrials.gov identifier, NCT06346340.

Indexed as

Cataract surgeryDry eyeOcular surface diseasePerfluorohexyloctane ophthalmic solution

Identifiers

PMID41588216
PMCPMC12901797

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.